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Abstract
Biomedical research encompasses diverse types of activities, from basic science (“bench”) to clinical medicine
(“bedside”) to bench-to-bedside translational research. It, however, remains unclear whether different types
of research receive citations at varying rates. Here we aim to answer this question by using a newly pro-
posed paper-level indicator that quantifies the extent to which a paper is basic science or clinical medicine.
Applying this measure to 5 million biomedical papers, we find a systematic citation disadvantage of clinical
oriented papers; they tend to garner far fewer citations and are less likely to be hit works than papers
oriented towards basic science. At the same time, clinical research has a higher variance in its citation. We
also find that the citation difference between basic and clinical research decreases, yet still persists, if longer
citation-window is used. Given the increasing adoption of short-term, citation-based bibliometric indicators
in funding decisions, the under-cited effect of clinical research may provide disincentives for bio-researchers
to venture into the translation of basic scientific discoveries into clinical applications, thus providing expla-
nations of reasons behind the existence of the gap between basic and clinical research that is commented
as “valley of death” and the commentary of “extinction” risk of translational researchers. Our work may
provide insights to policy-makers on how to evaluate different types of biomedical research.
Keywords: biomedicine, basic research, clinical medicine, citation analysis, bias
1. Introduction
Citation-based indicators, such as h-index (Hirsch, 2005) and Journal Impact Factor (Garfield, 2006),
have been increasingly employed in the evaluation of research performance, playing a significant role in
various decision-making processes, like funding, hiring, and promotion, and in the ranking of diverse actors
in science. Such practice, however, has received criticisms (MacRoberts and MacRoberts, 1989; Nature
Editorial, 2005; Seglen, 1997), and a major argument behind those criticisms is that citation data suffers
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from the presence of several biases. For example, it has been shown that citations have been inflating
over time (Persson et al., 2004), so that later papers on average are cited more than earlier ones. Another
bias is that there is a significant variation of citations for papers in different research fields (Bornmann
and Daniel, 2008); e.g., biology papers on average receive a larger number of citations than mathematics
papers. Recently, Wang et al. (2017) found that there is also bias against novel researches—papers that
make first-ever combinations of existing knowledge components; they are more likely to be hit works, but
display delayed recognition and are published in journals with low Impact Factor (IF). Given the widespread
usage of citation-based indicators, it is important to understand what other potential biases are and carry
out citation analysis in a less biased way.
In this article, we focus on biomedical research and investigate whether and to what extent another bias,
which we call research level bias, is present in citation data. Biomedicine is a broad area of science that
studies biological process of life and the cause and treatment of disease. It is characterized by diverse types
of research activities, ranging from basic science that advances the understanding of living organisms by
announcing scientific discoveries, to clinical research that studies the treatment of disease, to translational
research that aims for translating basic scientific discoveries into the development of useful clinical appli-
cations that benefit patients. The questions we seek to answer here are: Is there systematic difference in
citations for papers belonging to different types of researches? Does certain type of biomedical research
exhibit particular disadvantages in receiving citations? These questions are important because the existence
of the research level bias in citations is of particular concerns for funding agencies and institutions, given
that they have increasingly relied on citation-based bibliometric indicators for research evaluation. To the
best of our knowledge, our work is the first to answer these questions systematically. We also remark that
this potential research level bias goes beyond the well-known and widely discussed field bias, because one
field may encompass more than one type of researches. For instance, within oncology, a well-operationalized
field1, papers can be basic science about the identification of tumor suppressing genes, or clinical research
about the development of cancer drugs.
Here, drawing on more than 5 million biomedical research papers indexed in the MEDLINE database and
published in a 23-year period (1980–2002), we find that there is disadvantage in getting citations for clinical
research papers. Our analysis relies on a newly minted paper-level indicator that quantifies the extent to
which a biomedical paper is oriented towards basic science or clinical research. Our results suggest that
papers that are oriented towards clinical research tend to garner far fewer citations than papers oriented
1In the Web of Science database, there is a Subject Category label called “Oncology.”
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towards basic science. Clinical papers also have a much lower chance for being ranked in the top 1% most
cited papers among those in the same field and the same year. Our further analysis using short-, medium-,
and long-term citation windows reveals that this citation disadvantage weakens, but still persists, as we
increase window length.
To the extent of the reported citation disadvantage of clinical research is a long-standing concern about
the existence of the gap between basic biomedical research and clinical research. It has been argued that
tremendous progresses made in basic science do not give rise to commensurate, useful clinical applications
that benefit patients (Butler, 2008). In the attempt to bridge this gap, funding bodies have been increasingly
emphasized the demonstration of societal impact (e.g., impact on patients) of research and made ongoing
efforts to initialize large translational research programs like Clinical and Translational Science Awards (Zer-
houni, 2003). Translation, however, is a decade-long process with frequent failures (Contopoulos-Ioannidis
et al., 2008; Morris et al., 2011), which makes the academic performance evaluation a rather challenging task.
Convenient, citation-based metrics, such as the number of publications in high IF journals and h-index, are
instead adopted for the task. This, however, may provide disincentives for basic researchers to venture into
the translation of basic science results into clinical products, as clinical papers receive fewer citations, which
in turn are emphasized in performance evaluation. The citation disadvantage of clinical research, therefore,
may help explain and further reinforce the current situation in the biomedical research enterprise, where the
gap has been described as the “valley of death” (Butler, 2008; Pasterkamp et al., 2016) and “translational
researchers are at risk of becoming ‘extinct’” (Pasterkamp et al., 2016). From a policy perspective, our
findings may provide insights to policy-makers on how to evaluate different types of biomedical research.
2. Literature review
2.1. Basic and clinical research
The notions of basic and clinical research have long been adopted by diverse fields to characterize various
aspects of the biomedical research enterprise. Moses et al. (2005), for example, examined U.S. funding trends
of basic and clinical research received from government, foundations, industry and other sources. Zinner
and Campbell (2009) conducted a mailed survey of faculty in U.S. academic medical centers, asking about
type of research (basic, clinical trials, epidemiology etc.) as well as funding, publishing, and patenting
behavior. They found that 33.6% of faculty exclusively performed basic research, in contrast to 9.1%
translational researchers. Levitt and Levitt (2017) looked at the age structure of basic science faculty who
are eligible for grant and found a steady decrease of the number of such faculty. Their analysis further
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indicates that the fraction of faculty who received R01 grant from the U.S. National Institutes of Health
(NIH) decreased for younger faculty and increased for older ones. Many studies set out to understand the
life-cycle of translational science and showed that this process takes many years and fails frequently (Collins,
2011; Contopoulos-Ioannidis et al., 2008; Khoury et al., 2010; Morris et al., 2011; Williams et al., 2015).
Finally, many scholars have argued for the public support of basic science (Lane and Bertuzzi, 2011; Moses
and Martin, 2011; Press, 2013), and several prior works in the innovation literature studied the returns
of investments in science and the interactions between basic scientific advances and practical technological
progress (Li et al., 2017; Toole, 2012).
2.2. Indicators for research level
Given the widespread use of the two terms, how can one operationalize them at the individual paper
level? How to infer whether a given paper is basic science or clinical research? Such an operationalization is
especially important for science and technology studies, because the availability of an indicator for research
level opens venues for systematic investigations of the aforementioned characterizations of biomedicine. In
the present work, we study how the research level of a paper is associated with the number of citations it
receives.
The earliest study that proposed an indicator for research level may be Narin et al. (1976), where they
subjectively classified journals into four levels of biomedical research. They are, in the order from most basic
to most clinical, basic research (L4), clinical investigation (L3), clinical mix (L2), and clinical observation
(L1). For each level, they further selected one prototypical journal: Journal of Biological Chemistry for
L4, Journal of Clinical Investigation for L3, New England Journal of Medicine for L2, and Journal of the
American Medical Association for L1. All papers published in a journal then carry the research level of
the journal. This four-level categorization has later been used by Narin and his colleagues in studies about
patent-to-paper citations, showing that papers that are cited by patents are mostly from L4 and therefore
arguing the advantage of basic research in generating technological innovations (McMillan et al., 2000; Narin
et al., 1997). The classification schema has also been employed in research evaluation (Lewison and Dawson,
1998; Lewison and Devey, 1999).
Recent proposals of research level indicators focused on papers rather than journals and leveraged Medical
Subject Heading (MeSH) to quantify research level. MeSH terms are hierarchically-organized controlled
medical vocabularies. They are maintained and used by the U.S. National Library of Medicine (NLM) to
index and retrieve MEDLINE papers. The MeSH terms of a paper describe the content of the research, and
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the assignment of terms to papers are performed not by authors but rather by trained staffs at NLM, to
guarantee the consistence of the assignment.
The main idea behind using MeSH terms to infer research level is that certain organism-related terms
are for labeling the type of subjects studied, which corresponds to the key element in the commonly-adopted
operational definitions of basic and clinical research. Basic science, for example, has been operationalized
as researches with experiments performed at the level of cell and non-human animals. Those researches are
conducted without a specific application objective (e.g., developing a new drug), but rather to make scientific
discoveries2. Basic research often uses model organism like Caenorhabditis elegans as experiment subject.
The appearance of cell and animal MeSH terms in a paper therefore is indicative that it is basic science.
Clinical research, on the other hand, has been defined as studies with human subjects3. The presence of the
term “Humans”4 in a paper can be used as a heuristic that the paper is about clinical research.
Based on this idea, Weber (2013) partitioned MEDLINE papers into seven categories, according to
whether cell-, animal-, and human-related terms are present in the list of MeSH terms of a paper. The most
basic papers are those with only cell and animal terms, papers with only human terms are instead considered
as the most clinical, and papers with both are in between. Similarly, Li et al. (2017) assigned NIH grants
to different animal kingdom categories, from virus, prokaryote up to primates and humans, based on the
MeSH terms that were inferred from the texts of grant abstracts. They found that basic and applied grants
are equal likely in generating papers that are subsequently cited by patents.
2.3. Citation difference by research level
Our research question is how the research level of a paper is associated with the number of citations it
receives. Despite a few proposals of indicators for research level have been introduced as described above,
this question has remained largely unexplored, and existing works seem to generate competing answers.
Using visualization techniques, van Eck et al. (2013) showed that clinical words are associated with less
citations. Pasterkamp et al. (2016) looked at journals that belong to various stages of the drug development
pipeline (drug target discovery, pre-clinical studies, clinical trials, etc.) and found that for journals with the
highest IF at each stage, there is a IF valley—journals that are located between basic and clinical research
have the lowest IF. This observation reinforces the “valley of death” notion (Butler, 2008). Opthof (2011)
examined papers published in Circulation in year 1998 and found that clinical papers seem to have more
2Curiosity Creates Cures: The Value and Impact of Basic Research; https://www.nigms.nih.gov/Education/Pages/
factsheet_CuriosityCreatesCures.aspx
3https://grants.nih.gov/grants/glossary.htm#ClinicalResearch
4Unique ID D006801; https://meshb.nlm.nih.gov/record/ui?ui=D006801
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Figure 1: Case studies of level scores of individual papers. The histogram shows the distribution of scores for all the 5 million
papers included in our sample. Vertical lines mark the scores of three papers, which are, from left to right, (1) Nature 391,
806 (1998) (Fire et al., 1998); (2) NEJM 317, 185 (1987) (Fischl et al., 1987); and (3) NEJM 328, 1450 (1993) (Rimm et al.,
1993).
citations than basic papers. Finally, Fu and Aliferis (2010) used content based features as derived from
MeSH terms to predict citations of biomedical papers. The fact that there is a predictive power of MeSH
terms suggests that there may be indeed citation difference for papers with different terms.
3. Level score: an indicator for biomedical research level
To study how research level is linked to citations, we adopted a newly minted measure called “level score”
(LS) as the indicator for research level (Ke, 2019). LS is a paper-level indicator that quantifies the extent
to which a biomedical paper is oriented towards basic science or clinical research. By construction, a paper
with LS closer to -1 is more oriented towards basic science and 1 clinical research. Compared with previous
indicators that are nominal values, LS is continuous. The reason for continuity is because discrete value
loses its ability in distinguishing papers with qualitatively distinct extent of basicness. For example, more
than half of MEDLINE papers are associated with only human related MeSH terms, and existing indicators
consider them with the same value of basicness. Their actual research levels, however, can be very broad:
Phase I clinical trial papers are more basic than Phase IV papers, which are more basic than nursing papers.
LS can instead capture this difference.
Here we briefly describe the main idea behind the calculation of LS and show the values for several
exemplar papers, and the details of the calculation are provided in Ke (2019). The derivation of LS is still
based on the idea that certain MeSH terms indicates the level of experiment and is inspired from recent
advances in representation learning in machine learning literature. In particular, it has been shown that
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Table 1: Level score and MeSH terms of three selected papers. Appliedness scores of terms are in parentheses.
Paper LS MeSH terms
Nature 391, 806 (1998) -0.207 Animals (-0.295); Caenorhabditis elegans (-0.169);
Caenorhabditis elegans Proteins (-0.186); Calmodulin-Binding Proteins (-0.252);
Gene Expression Regulation (-0.291); Genes, Helminth (-0.167);
Helminth Proteins (-0.231); Muscle Proteins (-0.223); Phenotype (-0.038);
RNA, Antisense (-0.307); RNA, Double-Stranded (-0.116)
NEJM 317, 185 (1987) 0.257 AIDS-Related Complex (0.228); Acquired Immunodeficiency Syndrome (0.447);
Antiviral Agents (-0.098); Clinical Trials as Topic (0.486);
Double-Blind Method (0.428); Female (–); Humans (0.580); Male (–);
Opportunistic Infections (0.262); Pneumonia, Pneumocystis (0.225);
Random Allocation (0.520); Sarcoma, Kaposi (0.253);
Thymidine (-0.348); Zidovudine (0.098)
NEJM 328, 1450 (1993) 0.448 Adult (0.631); Ascorbic Acid (-0.050); Carotenoids (0.078);
Confidence Intervals (0.748); Coronary Disease (0.450); Diet (0.224);
Follow-Up Studies (0.631); Humans (0.616); Male (–); Middle Aged (0.578);
Prospective Studies (0.687); Risk Factors (0.754); Vitamin E (0.030)
No appliedness scores are assigned to “Male” and “Female,” because they were excluded from the calculation, as they do not
have tree numbers, which are required to check whether terms are cell-, animal-, or human-related.
vector-representations of words that are learned from large-scale text corpora capture semantic relationships
between words, as exemplified by the equation v(king)−v(man)+v(woman) ≈ v(queen), where v(·) denotes
the vector of a word (Mikolov et al., 2013a,b). From these vectors, one can induce the gender dimension by
vector difference of pairs of words; a simple arithmetic operation of the above equation gives us v(king) −
v(queen) ≈ v(man)−v(woman), where both v(king)−v(queen) and v(man)−v(woman) are instances of the
gender axis. Averaging over all these pairs of words (e.g., male and female) yields the gender dimension. One
can then project a word onto the gender dimension to study the extent of its similarity to male and female.
For example, studies have shown that—based on vectors learned from text corpora—computer programmer
is more to male than female, and further found that this type of analogy reflects societal bias, which can be
quantified through word vectors (Garg et al., 2018).
The calculation of LS resembles the process described above. First, popular methods are used to learn
vector-representations of MeSH terms5. Then, in the same way for identifying the gender axis, the translation
axis (TA)—a vector pointing from basic science MeSH terms to clinical research terms—is identified in the
vector space, where cell- and animal-related terms are used as basic science terms and human-related terms
as clinical. Next, each MeSH term are projected onto TA to obtain its “appliedness” score. The LS of a
paper is the average appliedness score of its MeSH terms, indicating averaged position of its MeSH terms
5MeSH terms are organized into a hierarchy with 16 branches, and most terms are associated with one or more tree numbers,
indicating their locations in the tree structure. Only terms that have tree numbers and are located in branches A–E, G, M,
and N are considered.
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on TA.
Note that when calculating LS of a focal paper, only MeSH terms that appeared in papers published in the
last 5 years were considered. This is based on the consideration that biomedical research has been evolving.
For example, Ke (2019) showed some MeSH terms whose appliedness scores have exhibited noticeable changes
during the studied period. One may, therefore, concern if the scores have also changed for some very general
terms such as “Humans.” Figure A.1 shows that this is not the case; its appliedness score remains relatively
stable over time, exhibiting a similar trend to the average of all terms.
To demonstrate the validity of LS, let us present some case studies of individual papers. In Figure 1, we
first show the histogram of LS for all the 5 million papers in our sample (see § 4.1 for sample selection), serving
as the background distribution against which we compare with several exemplar papers. The histogram
exhibits bimodality, with the two modes corresponding to basic science and clinical medicine. Bimodality
also indicates relatively less amount of published translational science papers compared to either basic or
clinical papers, reflecting the gap between basic and clinical science.
On top of the histogram, we highlight LS of the following papers. The first one [Nature 391, 806 (1998)]
discovered the RNA interference phenomenon and wined the 2006 Nobel Prize in Physiology or Medicine
(Fire et al., 1998). The first row in Table 1 lists the 11 MeSH terms associated to the paper and their
appliedness scores in parentheses. Two terms, namely “Animals” and “Caenorhabditis elegans,” describe
that the research was conducted on the Caenorhabditis elegans model organism6, and hence the paper is
considered as basic research using previous indicators. This is consistent with its LS, as suggested from
Figure 1 showing that the LS of the paper is located around the peak of the histogram that corresponds to
basic science, therefore indicating that it is a typical basic science paper.
The second paper [NEJM 317, 185 (1987)] is a highly-cited, clinical trial study that tested the effec-
tiveness of Zidovudine, a medication for HIV infection (Fischl et al., 1987). The second row in Table 1
enumerates its terms, and the fact that “Humans” is one of them means that the paper is categorized as
clinical medicine by existing indicators. The LS of the paper also indicates that it is a clinical paper, as seen
from Figure 1. Yet, LS can further capture that compared with typical clinical papers, it is more orientated
toward basic science. This is because the paper is about drug development, which follows the pipeline that
active drug ingredients first need to test on animals before entering the clinical trial stage.
The third paper [NEJM 328, 1450 (1993)] is a highly-cited, prospective study on the association between
dietary antioxidants consumption and the risk of primary coronary artery disease in men (Rimm et al., 1993).
6“Caenorhabditis elegans” is a descendant node of “Animals” in the MeSH tree.
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Its MeSH terms contain “Humans,” it is therefore classified as clinical research by existing indicators, as
well as by its LS. However, this paper is a typical epidemiology study, without testing new drugs, thus is
actually considered as less basic than the second paper. This can be captured by LS, as can be seen from
Figure 1 that its LS is larger than that of the second paper.
Going beyond individual examples, Ke (2019) presented systematic validations of LS. For example,
papers that are labeled as clinical trials are more oriented towards clinical research, with level scores getting
progressively larger for papers of later stages clinical trial. Aggregating LS onto the field level, it was shown
that cell biology and biochemistry are the most basic fields, whereas nursing the most clinical.
4. Data and methods
4.1. Sample selection
To address our research question, we analyze papers indexed in MEDLINE, a publicly available database
curated by the NLM for biomedical research literature. Our unit of analysis is a scientific paper. The papers
in our sample were published between 1980 and 2002, so that every paper has at least 15 years to garner
citations. We use Web of Science (WoS) data to obtain additional information about papers. In particular,
we limit our attention to papers that are designated as articles in WoS and further get their field labels,
as specified as WoS subject category, and their total citation counts, regardless of the fields where citing
papers are from. Our sample contains over 5 million papers. Table A.1 presents the top 30 largest fields
based on the number of papers in the sample. These fields accounts for 78.2% of all papers in the sample.
4.2. Dependent variables
The number of forward citations a paper receives has been widely used as an indicator for its scientific
impact. We introduce two groups of dependent variables. The first group is the total number of forward
citations that a focal paper has accrued within the 3-, 10-, and 15-year windows after its publication, denoted
as c3, c10, and c15, respectively. We consider different lengths of citation-windows to account for the paper-
and time-dependent tendency to acquire citations.
Since citations are heterogeneously distributed, spanning orders of magnitude (Table A.2), to capture the
right tail of citation distribution, our second group of dependent variables is binary variables that indicates
whether a focal paper is a hit one, defined as its total citation count is ranked into the top 1% among all
papers in the same field and the same publication year. We use the same three window lengths, and the
three dependent variables are similarly denoted as h3, h10, and h15.
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4.3. Independent variables
Our main independent variable of interest is the level score of a focal paper, denoted as ls.
In light of prior research, we consider the following control variables. The first is the number of authors,
as previous studies have repeatedly demonstrated the increasing prevalence of collaboration in knowledge
production (Wuchty et al., 2007) and the positive association between collaboration and citations (Bornmann
et al., 2012; Didegah and Thelwall, 2013; Fanelli, 2013; Peng and Zhu, 2012). The second control variable is
whether a focal paper involves international collaboration, which has been shown to have a positive link to
citations (Sin, 2011). The third is the number of MeSH terms, as it has a positive effect on citations (Chai
and Menon, 2019).
Table A.2 reports the summary statistics of all the variables introduced. Figure A.2 shows the distribu-
tions of non-indicator variables except LS, which has been shown in Figure 1.
Aside from the above control variables, we include the field and publication year fixed effects. Therefore,
our estimations of the effect of research level on citations are within the same field but not across fields.
Publication year fixed effect is included to address the concern that ignoring year would make it an omitted
variable; it controls for characteristics that are fixed within a year but vary across time, such as the number
of publications and the amount of funding.
4.4. Model specification
We use generalized negative binomial (GNB) regression, as provided by the gnbreg function in STATA,
to model the association between research level and citation count. We choose GNB because (1) it can
model over-dispersed count variable, which is the case for citation count, and (2) it can model not only the
mean but also the dispersion parameter. The model specification is as follows:
ci = β0 + β1 · lsi + γ · controlsi + δi + ηi + εi , (1)
where β1 is the coefficient of interest for the research level independent variable, δi is a dummy variable for
WoS subject category (field fixed effect), ηi is a dummy for publication year, and εi is the noise term.
We employ logistic regression model to estimate the effect of level score on being a hit paper, controlling
for other confounding variables. The model specification is similar to the GNB one.
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Table 2: Mean and standard deviation of citations for papers grouped by their level scores.
c3 c10 c15
Level score range Mean Std. Dev. Mean Std. Dev. Mean Std. Dev.
< −0.308 13.691 24.619 34.425 66.751 41.522 84.190
< −0.007 10.766 20.601 29.606 69.053 37.723 98.234
< 0.295 6.706 13.976 20.015 48.280 26.372 80.252
< 0.596 5.049 11.702 16.736 39.610 22.859 58.260
≥ 0.596 4.445 10.034 17.241 39.490 25.199 67.556
5. Results
5.1. Clinical papers are undercited
Table 2 groups papers into 10 categories base on their LS and show mean and standard deviation summary
statistics of citations for papers in each group. We observe that average number of citations decreases as we
move along the spectrum from basic to clinical research.
We further test whether the observation showed in Table 2 holds after controlling for other confounding
factors. We run negative binomial regressions to estimate 3-, 10-, and 15-year citations of papers and report
the full regression results in Tables A.3–A.5. These results fully support Table 2, reassuring a negative
association between research level and citation counts.
Let us first describe the results for 3-year citations (Table A.3). Model 1 in Table A.3 indicates that
after controling only for the publication year fixed effect, a one-unit increase in level score is linked to 73%
(e−1.309 − 1) decrease of c3. Model 2 in Table A.3 suggests that after controlling for the field fixed effect,
for each one-unit increase in level score, the expected citation count in 3 years decreases by 39%. If we
additionally include the publication year fixed effect, the effect size is more pronounced—49% decrease, as
shown in Model 3. In Model 4, we further consider all independent control variables and find that one-unit
increase in LS translates to 41% significant decrease of 3-year citations. As side results, Model 4 reinforces
several previous studies; that is, both the number of authors and international collaboration are positively
linked to the number of citations.
Next, we explore how the effect of research level on citations may have changed over time. In doing so, we
divide the full sample into three disjoint subsamples, each corresponding to the decade of publication year.
Models 5–7 in Table A.3 display the modeling results. We find that the effect size decreases over time; for
papers published in 1980s, one-unit increase in level score is associated with a sizable (52%) decrease of 3-
year citations, and such negative effect had weakened to 39% in 1990s and 34% in 2000–2002. Understanding
factors behind this shrinking effect is beyond the scope of this work, but serves as an important future study.
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Figure 2: Effect sizes of level score on citations. In all cases, we use negative binomial regression considering field and publication
year fixed effects and other control variables.
We nevertheless conjecture that an account for this is the growing importance of clinical medicine.
The results presented so far are based on 3-year citations. To understand how the effect of research level
on citations may vary for different lengths of citation windows, we separately model citations in 10 and 15
years, which serve as the proxies for medium- and long-term scientific impact, whereas 3-year citation is
for short-term impact. In both cases, we consider the full sample as well as subsamples of papers grouped
by decade. Tables A.4 and A.5 respectively present the results for 10- and 15-year citations. To facilitate
comparisons, we summarize all the modeling results in Figure 2, where we plot the effect sizes (eβ1 − 1) of
LS on citations.
Figure 2 first indicates that LS consistently has a negative effect on citations. This means that papers
that are more orientated towards clinical medicine tend to acquire fewer citations. The extent, however,
varies across time and citation-window length. Looking at the full sample, Figure 2 (see also Models 4 in
Tables A.3–A.5) suggests a stronger effect for shorter citation window. In particular, one-unit increase in
LS is associated with 41% decrease of 3-year citations (c3), 22% decrease of c10 and 12% decrease of c15.
Turning to the decade subsamples, we observe a similar weakening influence of research level on citations
as we increase window length. For papers published in 1980s, the size of the negative effect decreases from
52% for c3 to 40% for c10 to 31% for c15 (Models 5 in Tables A.3–A.5). For papers in 1990s, the size
shrinks from 39% for c3 to 19% for c10 to 8% for c15 (Models 6 in Tables A.3–A.5). These results signify
that life-cycles of papers’ citations may differ by their research levels: Shortly after publication, citations of
clinical orientated papers may be less saturated, we thus observe a strong effect of research level on citations;
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as we increase the citation window, their citations become more saturated, and the effect correspondingly
becomes weaker.
Aside from modeling mean citations, we also examine the dispersion of citations. Tables A.6–A.8,
which provide estimates from GNB models, demonstrate a consistently positive association between LS and
dispersion of citations, regardless of window length and publication time. This implies that clinical oriented
papers have higher dispersion in citations.
5.2. Probability of hit papers
As citation count exhibits over-dispersion, we investigate the right tail of the distributions and model
the probability of breakthrough papers. We again use 3-, 10-, and 15-year citations as the short-, medium-,
and long-term scientific impact, and utilize logistic regression to model whether a paper is among the top
1% most cited ones clustered by field and publication year. Similar to the regression case, we summarize all
the effect size results of LS in Figure 3, and model estimates are instead detailed in Tables A.9–A.11.
Focusing on the full sample, Figure 3 (see also Model 4 in Table A.9) shows that after controlling for
field and year fixed effects and all other confounders, a one-unit increase of LS is linked to a 53% (e−0.754 -
1) significant decrease in the odds of being made in the top 1% most cited papers based on 3-year citations.
For 10-year citations, LS is still negatively correlated with being a “hit” paper, but the effect size is much
smaller than the 3-year citation case, reaching to only 17% (Model 4 in Table A.10). As we continue to
expand the length of citation-window to 15 years, we observe that there is actually a 8% increase in the
odds of becoming hit papers (Model 4 in Table A.11).
We explore time trends of the effect of research level on being a hit paper. For papers in 1980s, we find a
negative yet weakening effect. Each one-unit increase of LS translates to 71%, 58%, and 42% significant de-
crease in the odds of being recognized as breakthroughs after 3, 10, and 15 years of publication, respectively.
For papers in the 1990s, we see a negative-to-positive transition of the effect, similar to the full sample case.
6. Concluding discussion
Biomedical research has two broad goals: advancing the understandings of living organisms through basic
science and improving human health through clinical research. The purpose of this work was to understand
whether there is any systematic differences in the amount of citations received for the two types of research.
This is important, because citation-based indicators for scientific impact have been increasingly used for
research evaluation. We have used a paper-level indicator that quantifies the extent of basicness and studied
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Figure 3: Effect sizes of level score on being ranked into the top 1% most cited papers in the same field and year. In all cases,
we use logistic regression considering field and publication year fixed effects and other control variables.
its association with short-, medium-, and long-term citations for a large-scale corpus of more than 5 million
papers published in 1980-2002. Our analysis has pointed out the disadvantage of clinical orientated research
in accruing citations; clinical papers tend to have fewer citations than basic papers and are less likely to
become hit works. We have further found that such difference is more pronounced for short-term citations.
These results may speak to the policy literature. Bio-researchers appear to be facing a dilemma posing
by current science policy. On one hand, a proven record of individual excellence in publications and citations
is underscored in funding and tenure decisions. On the other, the public, government, and funding bodies
have been increasingly calling for researchers to demonstrate the direct impact of their research on the
improvement of human health and the societal impact in general. The demonstration of clinical relevance
requires the translation of basic scientific discoveries into clinical applications, from which patients can
benefit. This process, however, may take decades with frequent failures (Contopoulos-Ioannidis et al.,
2008), which results in less number of publications and less amount of citations accrued, which in turn
makes translational researchers less competitive in evaluation. This may provide disincentive to researchers
to work on the translation of basic science, resulting in a gap between basic science and clinical research
that is coined as “valley of death” (Butler, 2008). Given the current citation under-appreciation of clinical
research, funding bodies may seek to have comprehensive evaluation of output beyond scholarly publications
and short-term based citations. Examples can be looking at citations in other types of documents such as
clinical guidance (Grant et al., 2000) and drug development documents (Williams et al., 2015).
Our work also adds to the bibliometrics literature that has studied potential biases in citation data. One
14
of the most well-known biases is the field bias (Bornmann and Daniel, 2008); that is, papers in certain fields
on average have more citations than other fields. Reasons for such difference may include varying number of
papers and number of references in a paper. Many methods have been proposed in attempting to alleviate
this problem (Radicchi et al., 2008). The key idea behind these methods is to compare a paper’s raw number
of citations with citations of papers in the same field, resulting in field-normalized indicators. This procedure
considers cross-field citation difference only, thus fails to account for within-filed case, which, as we have
shown, happens for papers that are in the same field but belong to different types of researches. Field-
normalized indicators, therefore, are not able to correct research level bias. Proposing citation indicators
that can mitigate such bias remains to be an important future work.
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Figure A.1: Appliedness scores of selected MeSH terms over time.
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Figure A.2: Distributions of variables.
Table A.1: The number and percentage of papers in the top 30 largest fields in our corpus.
Field Papers Percentage
Biochemistry & Molecular Biology 524373 10.44
Medicine, General & Internal 263400 5.24
Pharmacology & Pharmacy 228988 4.56
Neurosciences 222744 4.43
Surgery 221762 4.41
Immunology 199624 3.97
Oncology 198047 3.94
Cardiac & Cardiovascular Systems 146685 2.92
Endocrinology & Metabolism 134664 2.68
Radiology, Nuclear Medicine & Medical Imaging 121995 2.43
Cell Biology 117688 2.34
Public, Environmental & Occupational Health 108608 2.16
Clinical Neurology 101155 2.01
Microbiology 100888 2.01
Genetics & Heredity 97359 1.94
Multidisciplinary Sciences 93317 1.86
Physiology 92344 1.84
Urology & Nephrology 85991 1.71
Obstetrics & Gynecology 82911 1.65
Pediatrics 81059 1.61
Veterinary Sciences 80957 1.61
Ophthalmology 79952 1.59
Gastroenterology & Hepatology 79522 1.58
Hematology 75930 1.51
Pathology 72687 1.45
Psychiatry 72197 1.44
Dentistry, Oral Surgery & Medicine 69106 1.38
Dermatology 61867 1.23
Medicine, Research & Experimental 60229 1.20
Virology 53014 1.06
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Table A.2: Summary statistics for all the variables used in our analysis.
Variable Mean Std. Dev. Min Max N
c3 8.033 17.068 0 3933 5 026 235
c10 23.387 56.281 0 30327 5 026 235
c15 30.504 82.453 0 49315 5 026 235
h3 0.0104 0.101 0 1 4 985 532
h10 0.010 0.100 0 1 4 985 532
h15 0.010 0.100 0 1 4 985 532
year 1992.631 6.563 1980 2002 5 026 235
ls 0.114 0.310 -0.609 0.897 5 026 235
authornum 4.082 2.690 1 546 5 026 235
authorintl 0.109 0.312 0 1 4 112 865
meshnum 12.19 4.447 1 60 5 026 235
Table A.3: Negative binomial regression modeling of 3-year citations.
(1) (2) (3) (4) (5) (6) (7)
c3 1980–2002 1980–2002 1980–2002 1980–2002 1980–1989 1990–1999 2000–2002
ls -1.309∗∗∗ -0.496∗∗∗ -0.678∗∗∗ -0.531∗∗∗ -0.736∗∗∗ -0.496∗∗∗ -0.409∗∗∗
(0.00191) (0.00274) (0.00280) (0.00294) (0.00587) (0.00412) (0.00599)
ln authornum 0.310∗∗∗ 0.365∗∗∗ 0.295∗∗∗ 0.264∗∗∗
(0.00101) (0.00194) (0.00145) (0.00206)
meshnum 0.0427∗∗∗ 0.0604∗∗∗ 0.0432∗∗∗ 0.0358∗∗∗
(0.000134) (0.000333) (0.000188) (0.000234)
authorintl 0.146∗∗∗ 0.105∗∗∗ 0.160∗∗∗ 0.161∗∗∗
(0.00174) (0.00460) (0.00242) (0.00297)
Constant 1.810∗∗∗ 1.643∗∗∗ 1.567∗∗∗ 0.899∗∗∗ 0.994∗∗∗ 0.697∗∗∗ 1.014∗∗∗
(0.00363) (0.0532) (0.0535) (0.0604) (0.109) (0.0918) (0.108)
Field fe X X X X X X
Year fe X X X X X X
Observations 5024732 5024732 5024732 4111637 1172896 1997524 941217
Standard errors in parentheses
∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001
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Table A.4: Negative binomial regression modeling of 10-year citations.
(1) (2) (3) (4) (5) (6) (7)
c10 1980–2002 1980–2002 1980–2002 1980–2002 1980–1989 1990–1999 2000–2002
ls -0.963∗∗∗ -0.185∗∗∗ -0.397∗∗∗ -0.246∗∗∗ -0.510∗∗∗ -0.206∗∗∗ -0.0884∗∗∗
(0.00181) (0.00265) (0.00270) (0.00283) (0.00574) (0.00392) (0.00579)
ln authornum 0.293∗∗∗ 0.348∗∗∗ 0.280∗∗∗ 0.246∗∗∗
(0.000980) (0.00191) (0.00138) (0.00199)
meshnum 0.0429∗∗∗ 0.0632∗∗∗ 0.0434∗∗∗ 0.0353∗∗∗
(0.000130) (0.000327) 0.000181) (0.000229)
authorintl 0.144∗∗∗ 0.0991∗∗∗ 0.155∗∗∗ 0.164∗∗∗
(0.00171) (0.00461) (0.00236) (0.00291)
Constant 2.832∗∗∗ 2.934∗∗∗ 2.836∗∗∗ 2.177∗∗∗ 2.155∗∗∗ 2.094∗∗∗ 2.588∗∗∗
(0.00360) (0.0519) (0.0517) (0.0576) (0.105) (0.0852) (0.107)
Field fe X X X X X X
Year fe X X X X X X
Observations 5024732 5024732 5024732 4111637 1172896 1997524 941217
Standard errors in parentheses
∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001
Table A.5: Negative binomial regression modeling of 15-year citations.
(1) (2) (3) (4) (5) (6) (7)
c15 1980–2002 1980–2002 1980–2002 1980–2002 1980–1989 1990–1999 2000–2002
ls -0.835∗∗∗ -0.0394∗∗∗ -0.277∗∗∗ -0.129∗∗∗ -0.371∗∗∗ -0.0876∗∗∗ 0.0117∗
(0.00182) (0.00268) (0.00272) (0.00286) (0.00579) (0.00396) (0.00590)
ln authornum 0.281∗∗∗ 0.335∗∗∗ 0.270∗∗∗ 0.233∗∗∗
(0.000994) (0.00193) (0.00140) (0.00204)
meshnum 0.0420∗∗∗ 0.0626∗∗∗ 0.0426∗∗∗ 0.0341∗∗∗
(0.000132) (0.000330) (0.000183) (0.000234)
authorintl 0.148∗∗∗ 0.102∗∗∗ 0.159∗∗∗ 0.169∗∗∗
(0.00174) (0.00466) (0.00240) (0.00298)
Constant 3.059∗∗∗ 3.263∗∗∗ 3.151∗∗∗ 2.501∗∗∗ 2.402∗∗∗ 2.451∗∗∗ 3.081∗∗∗
(0.00367) (0.0528) (0.0524) (0.0583) (0.106) (0.0850) (0.114)
Field fe X X X X X X
Year fe X X X X X X
Observations 5024732 5024732 5024732 4111637 1172896 1997524 941217
Standard errors in parentheses
∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001
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Table A.6: Negative binomial regression modeling of dispersion of 3-year citations.
(1) (2) (3) (4) (5) (6) (7)
lnalpha 1980–2002 1980–2002 1980–2002 1980–2002 1980–1989 1990–1999 2000-2002
ls 0.498∗∗∗ 0.406∗∗∗ 0.499∗∗∗ 0.344∗∗∗ 0.397∗∗∗ 0.308∗∗∗ 0.363∗∗∗
(0.00229) (0.00352) (0.00365) (0.00407) (0.00805) (0.00570) (0.00865)
ln authornum -0.0863∗∗∗ -0.133∗∗∗ -0.0636∗∗∗ -0.0651∗∗∗
(0.00140) (0.00264) (0.00199) (0.00297)
meshnum -0.0253∗∗∗ -0.0244∗∗∗ -0.0258∗∗∗ -0.0283∗∗∗
(0.000187) (0.000453) (0.000261) (0.000345)
authorintl -0.0859∗∗∗ -0.0770∗∗∗ -0.0914∗∗∗ -0.103∗∗∗
(0.00250) (0.00654) (0.00344) (0.00446)
Constant 0.510∗∗∗ 0.240∗∗∗ 0.266∗∗∗ 0.743∗∗∗ 0.969∗∗∗ 0.823∗∗∗ -0.0185
(0.00433) (0.0689) (0.0688) (0.0743) (0.111) (0.118) (0.198)
Field fe X X X X X X
Year fe X X X X X X
Observations 5024732 5024732 5024732 4111637 1172896 1997524 941217
Standard errors in parentheses
∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001
Table A.7: Negative binomial regression modeling of dispersion of 10-year citations.
(1) (2) (3) (4) (5) (6) (7)
lnalpha 1980–2002 1980–2002 1980–2002 1980–2002 1980–1989 1990–1999 2000-2002
ls 0.402∗∗∗ 0.314∗∗∗ 0.414∗∗∗ 0.262∗∗∗ 0.276∗∗∗ 0.235∗∗∗ 0.303∗∗∗
(0.00197) (0.00297) (0.00307) (0.00343) (0.00663) (0.00483) (0.00737)
ln authornum -0.112∗∗∗ -0.163∗∗∗ -0.0864∗∗∗ -0.0884∗∗∗
(0.00117) (0.00218) (0.00169) (0.00251)
meshnum -0.0245∗∗∗ -0.0235∗∗∗ -0.0251∗∗∗ -0.0267∗∗∗
(0.000161) (0.000378) (0.000226) (0.000298)
authorintl=1 -0.0667∗∗∗ -0.0571∗∗∗ -0.0696∗∗∗ -0.0879∗∗∗
0.00221) (0.00571) (0.00306) (0.00392)
Constant 0.560∗∗∗ 0.369∗∗∗ 0.413∗∗∗ 0.862∗∗∗ 1.066∗∗∗ 0.859∗∗∗ 0.234
(0.00370) (0.0527) (0.0530) (0.0570) (0.0884) (0.0882) (0.135)
Field fe X X X X X X
Year fe X X X X X X
Observations 5024732 5024732 5024732 4111637 1172896 1997524 941217
Standard errors in parentheses
∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001
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Table A.8: Negative binomial regression modeling of dispersion of 15-year citations.
(1) (2) (3) (4) (5) (6) (7)
lnalpha 1980–2002 1980–2002 1980–2002 1980–2002 1980–1989 1990–1999 2000-2002
ls 0.409∗∗∗ 0.329∗∗∗ 0.422∗∗∗ 0.271∗∗∗ 0.282∗∗∗ 0.249∗∗∗ 0.314∗∗∗
(0.00192) (0.00288) (0.00298) (0.00333) (0.00641) (0.00470) (0.00715)
ln authornum -0.122∗∗∗ -0.172∗∗∗ -0.0952∗∗∗ -0.101∗∗∗
(0.00114) (0.00212) (0.00164) (0.00243)
meshnum -0.0245∗∗∗ -0.0236∗∗∗ -0.0250∗∗∗ -0.0267∗∗∗
(0.000157) (0.000367) (0.000220) (0.000290)
authorintl -0.0614∗∗∗ -0.0503∗∗∗ -0.0637∗∗∗ -0.0813∗∗∗
(0.00216) (0.00559) (0.00300) (0.00382)
Constant 0.603∗∗∗ 0.404∗∗∗ 0.465∗∗∗ 0.913∗∗∗ 1.101∗∗∗ 0.846∗∗∗ 0.377∗∗
(0.00361) (0.0503) (0.0507) (0.0545) (0.0854) (0.0837) (0.129)
Field fe X X X X X X
Year fe X X X X X X
Observations 5024732 5024732 5024732 4111637 1172896 1997524 941217
Standard errors in parentheses
∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001
Table A.9: Logistic regression modeling of top 1% papers based on 3-year citations.
(1) (2) (3) (4) (5) (6) (7)
h3 1980–2002 1980–2002 1980–2002 1980–2002 1980–1989 1990–1999 2000–2002
ls -0.415∗∗∗ -0.963∗∗∗ -1.010∗∗∗ -0.754∗∗∗ -1.250∗∗∗ -0.695∗∗∗ -0.272∗∗∗
(0.0148) (0.0214) (0.0219) (0.0239) (0.0441) (0.0340) (0.0535)
ln authornum 0.962∗∗∗ 0.957∗∗∗ 0.961∗∗∗ 0.987∗∗∗
(0.00947) (0.0169) (0.0136) (0.0214)
meshnum 0.0826∗∗∗ 0.124∗∗∗ 0.0840∗∗∗ 0.0599∗∗∗
(0.00106) (0.00239) (0.00150) (0.00205)
authorintl=1 0.299∗∗∗ 0.183∗∗∗ 0.330∗∗∗ 0.326∗∗∗
(0.0130) (0.0308) (0.0177) (0.0244)
Constant -4.527∗∗∗ -4.240∗∗∗ -4.252∗∗∗ -5.956∗∗∗ -6.319∗∗∗ -6.320∗∗∗ -6.722∗∗∗
(0.0262) (0.0208) (0.0325) (0.0403) (0.0550) (0.0492) (0.0778)
Field fe X X X X X X
Year fe X X X X X X
Observations 4985384 4985384 4985384 4080011 1159520 1984216 936193
Standard errors in parentheses
∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001
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Table A.10: Logistic regression modeling of top 1% papers based on 10-year citations.
(1) (2) (3) (4) (5) (6) (7)
h10 1980–2002 1980–2002 1980–2002 1980–2002 1980–1989 1990–1999 2000–2002
ls -0.205∗∗∗ -0.458∗∗∗ -0.480∗∗∗ -0.191∗∗∗ -0.871∗∗∗ -0.0625 0.405∗∗∗
(0.0148) (0.0216) (0.0222) (0.0243) (0.0449) (0.0344) (0.0542)
ln authornum 0.818∗∗∗ 0.805∗∗∗ 0.842∗∗∗ 0.786∗∗∗
(0.00940) (0.0167) (0.0135) (0.0212)
meshnum 0.0803∗∗∗ 0.125∗∗∗ 0.0809∗∗∗ 0.0570∗∗∗
(0.00108) (0.00242) (0.00152) (0.00210)
authorintl=1 0.280∗∗∗ 0.192∗∗∗ 0.296∗∗∗ 0.321∗∗∗
(0.0134) (0.0319) (0.0183) (0.0251)
Constant -4.562∗∗∗ -4.422∗∗∗ -4.424∗∗∗ -5.937∗∗∗ -6.235∗∗∗ -6.346∗∗∗ -6.673∗∗∗
(0.0265) (0.0210) (0.0330) (0.0406) (0.0551) (0.0495) (0.0779)
Field fe X X X X X X
Year fe X X X X X X
Observations 4985384 4985384 4985384 4080011 1159602 1984216 936193
Standard errors in parentheses
∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001
Table A.11: Logistic regression modeling of top 1% papers based on 15-year citations.
(1) (2) (3) (4) (5) (6) (7)
h15 1980–2002 1980–2002 1980–2002 1980–2002 1980–1989 1990–1999 2000–2002
ls -0.0880∗∗∗ -0.203∗∗∗ -0.212∗∗∗ 0.0786∗∗ -0.540∗∗∗ 0.207∗∗∗ 0.595∗∗∗
(0.0147) (0.0217) (0.0222) (0.0243) (0.0450) (0.0344) (0.0543)
ln authornum 0.733∗∗∗ 0.735∗∗∗ 0.760∗∗∗ 0.663∗∗∗
(0.00931) (0.0165) (0.0134) (0.0209)
meshnum 0.0765∗∗∗ 0.122∗∗∗ 0.0759∗∗∗ 0.0535∗∗∗
(0.00109) (0.00242) (0.00153) (0.00211)
authorintl=1 0.297∗∗∗ 0.209∗∗∗ 0.323∗∗∗ 0.322∗∗∗
(0.0135) (0.0321) (0.0184) (0.0253)
Constant -4.580∗∗∗ -4.516∗∗∗ -4.520∗∗∗ -5.909∗∗∗ -6.237∗∗∗ -6.274∗∗∗ -6.524∗∗∗
(0.0267) (0.0212) (0.0331) (0.0409) (0.0552) (0.0494) (0.0775)
Field fe X X X X X X
Year fe X X X X X X
Observations 4985384 4985384 4985384 4080011 1159602 1984216 936193
Standard errors in parentheses
∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001
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